MA29772B1 - Benzimidazoles substitues et procedes de preparation - Google Patents
Benzimidazoles substitues et procedes de preparationInfo
- Publication number
- MA29772B1 MA29772B1 MA30738A MA30738A MA29772B1 MA 29772 B1 MA29772 B1 MA 29772B1 MA 30738 A MA30738 A MA 30738A MA 30738 A MA30738 A MA 30738A MA 29772 B1 MA29772 B1 MA 29772B1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- methods
- substituted benzimidazoles
- formula
- benzimidazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
L'invention concerne des procédés de préparation de nouveaux composés benzimidazoles substitués de formule (I) utiles pour le traitement de troubles à médiation par kinase, où R1, R2, R3, R4, a, b, et c sont définis au sein de la formule (I).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71253905P | 2005-08-30 | 2005-08-30 | |
US71310805P | 2005-08-30 | 2005-08-30 | |
US73159105P | 2005-10-27 | 2005-10-27 | |
US77468406P | 2006-02-17 | 2006-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29772B1 true MA29772B1 (fr) | 2008-09-01 |
Family
ID=37434025
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30737A MA29915B1 (fr) | 2005-08-30 | 2008-03-11 | Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases |
MA30738A MA29772B1 (fr) | 2005-08-30 | 2008-03-11 | Benzimidazoles substitues et procedes de preparation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30737A MA29915B1 (fr) | 2005-08-30 | 2008-03-11 | Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases |
Country Status (37)
Country | Link |
---|---|
US (6) | US7482367B2 (fr) |
EP (2) | EP1924577B1 (fr) |
JP (4) | JP5210867B2 (fr) |
KR (2) | KR20080039965A (fr) |
AR (2) | AR057109A1 (fr) |
AT (2) | ATE526325T1 (fr) |
AU (2) | AU2006284666B2 (fr) |
BR (2) | BRPI0615314A2 (fr) |
CA (2) | CA2620472C (fr) |
CR (1) | CR9716A (fr) |
CU (1) | CU23784B7 (fr) |
CY (2) | CY1111871T1 (fr) |
DE (1) | DE602006021036D1 (fr) |
DK (2) | DK1926722T3 (fr) |
EA (1) | EA014230B1 (fr) |
EC (2) | ECSP088210A (fr) |
ES (1) | ES2374451T3 (fr) |
GE (1) | GEP20105004B (fr) |
GT (1) | GT200600394A (fr) |
HK (2) | HK1117519A1 (fr) |
HN (1) | HN2008000317A (fr) |
HR (2) | HRP20110312T1 (fr) |
IL (2) | IL189080A (fr) |
MA (2) | MA29915B1 (fr) |
MY (2) | MY148694A (fr) |
NI (1) | NI200800060A (fr) |
NO (1) | NO20081476L (fr) |
NZ (2) | NZ565450A (fr) |
PE (2) | PE20070335A1 (fr) |
PL (2) | PL1926722T3 (fr) |
PT (2) | PT1924577E (fr) |
RS (1) | RS52099B (fr) |
SI (2) | SI1924577T1 (fr) |
SM (1) | SMP200800022B (fr) |
TN (2) | TNSN08088A1 (fr) |
TW (2) | TWI387592B (fr) |
WO (2) | WO2007027950A1 (fr) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
GB0609378D0 (en) * | 2006-05-11 | 2006-06-21 | Novartis Ag | Organic compounds |
ATE459338T1 (de) * | 2006-07-21 | 2010-03-15 | Novartis Ag | Formulierungen für benzimidazolylpyridylether |
PE20080766A1 (es) * | 2006-08-30 | 2008-06-15 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
CA2662508A1 (fr) * | 2006-09-19 | 2008-07-10 | Novartis Ag | Biomarqueurs de modulation cible, efficacite, diagnostic et/ou pronostic pour les inhibiteurs de la raf |
CN101679372A (zh) * | 2007-03-02 | 2010-03-24 | 诺瓦提斯公司 | Raf激酶抑制剂的固体形式 |
MX2009012626A (es) * | 2007-05-23 | 2009-12-07 | Novartis Ag | Inhibidores de raf para el tratamiento de cancer de tiroides. |
AR066845A1 (es) | 2007-06-05 | 2009-09-16 | Takeda Pharmaceutical | Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer |
EP2181987B9 (fr) | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles et leur utilisation dans la prévention ou le traitement du cancer |
EP2184285B1 (fr) * | 2007-08-29 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique et son utilisation |
EP2288354A1 (fr) * | 2008-06-13 | 2011-03-02 | Novartis AG | Benzimidazoles substitués destinés au traitement de la neurofibromatose |
EP2310050A1 (fr) | 2008-07-11 | 2011-04-20 | Novartis AG | Combinaison de (a) un inhibiteur de phosphoinositide 3-kinase et de (b) un modulateur de voie ras/raf/mek |
WO2010051176A1 (fr) * | 2008-10-29 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques |
US8697874B2 (en) | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
JP2011020936A (ja) * | 2009-07-14 | 2011-02-03 | Lotte Co Ltd | 口臭除去剤 |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
WO2011044072A1 (fr) | 2009-10-05 | 2011-04-14 | Novartis Ag | Combinaison de raf-265 et d'un activateur d'ampk destinée à être utilisée dans le traitement d'une maladie proliférative |
BR112013012485A2 (pt) * | 2010-11-19 | 2016-09-06 | Glaxosmithkline Ip No 2 Ltd | método de tratamento com inibidor braf |
WO2012144463A1 (fr) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Agent thérapeutique pour les tumeurs |
WO2012145503A1 (fr) | 2011-04-21 | 2012-10-26 | Novartis Ag | Combinaisons pharmaceutiques |
JP6058009B2 (ja) | 2011-08-31 | 2017-01-11 | ノバルティス アーゲー | Pi3k−およびmek−阻害剤の相乗的な組合せ |
CA2849566C (fr) * | 2011-11-09 | 2021-02-09 | Cancer Research Technology Limited | Composes de type 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile et leur utilisation therapeutique |
CN108542906A (zh) | 2011-11-11 | 2018-09-18 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
CN103945831A (zh) | 2011-11-23 | 2014-07-23 | 诺华股份有限公司 | 医药制剂 |
EP2855448B1 (fr) | 2012-05-15 | 2017-02-08 | Cancer Research Technology Ltd | 5-[[4-[[morpholin-2-yl]méthylamino]-5-(trifluorométhyl)-2-pyridyl]- amino]pyrazine-2-carbonitrile et utilisations thérapeutiques de celui-ci |
CA2890663A1 (fr) | 2012-11-08 | 2014-05-15 | Novartis Ag | Combinaison pharmaceutique comprenant un inhibiteur de b-raf et un inhibiteur d'histone desacetylase et leur utilisation dans le traitement de maladies proliferatives |
AU2014233805B2 (en) | 2013-03-21 | 2018-10-18 | Array Biopharma Inc. | Combination therapy comprising a B-Raf inhibitor and a second inhibitor |
WO2015041533A1 (fr) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Association de rock et de la voie mapk |
WO2015041534A1 (fr) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk en combinaison avec raf/erk/mek |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
ME03558B (fr) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molécules d'anticorps anti-lag-3 et leurs utilisations |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (fr) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions pour le traitement du cancer |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
WO2016100882A1 (fr) | 2014-12-19 | 2016-06-23 | Novartis Ag | Polythérapies |
KR20170129802A (ko) | 2015-03-10 | 2017-11-27 | 아두로 바이오테크, 인코포레이티드 | "인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법 |
US9890187B2 (en) | 2015-06-26 | 2018-02-13 | Epos-Iasis Research And Development, Ltd. | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer |
ES2895910T3 (es) | 2015-06-30 | 2022-02-23 | Sequessome Tech Holdings Limited | Composiciones multifásicas |
WO2017019897A1 (fr) | 2015-07-29 | 2017-02-02 | Novartis Ag | Polythérapies comprenant des molécules d'anticorps contre tim -3 |
SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
CN105481944B (zh) * | 2015-12-10 | 2019-01-08 | 华南农业大学 | 一种苯并咪唑衍生物二肽铜配合物及其制备方法和应用 |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
WO2018009466A1 (fr) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
EP3579872A1 (fr) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk |
WO2018168899A1 (fr) * | 2017-03-15 | 2018-09-20 | 大日本住友製薬株式会社 | Procédé de production d'un dérivé de benzimidazole |
KR20230129627A (ko) | 2017-04-18 | 2023-09-08 | 일라이 릴리 앤드 캄파니 | 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물 |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
WO2018237157A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Molécules d'anticorps se liant à cd73 et leurs utilisations |
US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019133810A1 (fr) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Systèmes de culture de cellules souches pour cellules souches épithéliales colonnaires, et leurs utilisations |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2019232244A2 (fr) | 2018-05-31 | 2019-12-05 | Novartis Ag | Molécules d'anticorps anti-cd73 et leurs utilisations |
WO2020097396A1 (fr) * | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Dérivés de benzimidazole et dérivés d'aza-benzimidazole en tant qu'inhibiteurs de janus kinase 2 et leurs utilisations |
BR112021013637A2 (pt) | 2019-01-11 | 2021-09-14 | Naegis Pharmaceuticals Inc. | Inibidores da síntese de leucotrieno |
EP4031578A1 (fr) | 2019-09-18 | 2022-07-27 | Novartis AG | Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies |
AU2021267373A1 (en) | 2020-05-06 | 2022-12-08 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
WO2023086319A1 (fr) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2 |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3894037A (en) * | 1971-05-24 | 1975-07-08 | Ciba Geigy Corp | Certain isothiocyanobenzimidazoles |
CH634306A5 (de) * | 1977-04-12 | 1983-01-31 | Ciba Geigy Ag | Benzimidazolderivate, verfahren zu ihrer herstellung und anthelmintische mittel enthaltend diese verbindungen als wirkstoffe. |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4319039A (en) * | 1979-06-15 | 1982-03-09 | Merck & Co., Inc. | Preparation of ammonium salt of hypocholesteremic fermentation product |
US4294926A (en) * | 1979-06-15 | 1981-10-13 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
JPS5889191A (ja) | 1981-11-20 | 1983-05-27 | Sankyo Co Ltd | 3−ヒドロキシ−ml−236b誘導体の製造法 |
US4430502A (en) * | 1982-08-13 | 1984-02-07 | The Upjohn Company | Pyridinyl substituted benzimidazoles and quinoxalines |
US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4911165A (en) * | 1983-01-12 | 1990-03-27 | Ethicon, Inc. | Pliabilized polypropylene surgical filaments |
GB8307865D0 (en) * | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4782084A (en) * | 1987-06-29 | 1988-11-01 | Merck & Co., Inc. | HMG-COA reductase inhibitors |
US4885314A (en) | 1987-06-29 | 1989-12-05 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US4820850A (en) * | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
US4916239A (en) * | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
US5118853A (en) * | 1988-10-13 | 1992-06-02 | Sandoz Ltd. | Processes for the synthesis of 3-disubstituted aminoacroleins |
US5290946A (en) * | 1988-10-13 | 1994-03-01 | Sandoz Ltd. | Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes |
US4929437A (en) * | 1989-02-02 | 1990-05-29 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
US5189164A (en) * | 1989-05-22 | 1993-02-23 | Sandoz Ltd. | Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
JPH06759B2 (ja) * | 1989-09-22 | 1994-01-05 | ファイザー製薬株式会社 | 新規なベンゾイミダゾール化合物 |
US5420245A (en) * | 1990-04-18 | 1995-05-30 | Board Of Regents, The University Of Texas | Tetrapeptide-based inhibitors of farnesyl transferase |
US5041453A (en) * | 1990-05-30 | 1991-08-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4 |
FR2677020B1 (fr) * | 1991-05-31 | 1993-08-27 | Cird Galderma | Composes derives de benzimidazole, leur procede de preparation et leur utilisation dans les domaines therapeutique et cosmetique. |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
CA2111902A1 (fr) | 1992-12-21 | 1994-06-22 | Jack Beuford Campbell | Compositions antitumorales et methodes therapeutiques |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5409944A (en) * | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
CA2118985A1 (fr) | 1993-04-02 | 1994-10-03 | Dinesh V. Patel | Inhibiteurs heterocycliques de la farnesyl proteine transferase |
EP0763537A3 (fr) * | 1993-05-14 | 1997-10-22 | Genentech Inc | Inhibiteurs de la farnesyl-transferase non peptidiques |
US5602098A (en) * | 1993-05-18 | 1997-02-11 | University Of Pittsburgh | Inhibition of farnesyltransferase |
US5380738A (en) * | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
GB9602877D0 (en) | 1996-02-13 | 1996-04-10 | Merck Frosst Canada Inc | 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
EP0639573A1 (fr) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant |
US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
US5661152A (en) * | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5344991A (en) | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5484799A (en) | 1993-12-09 | 1996-01-16 | Abbott Laboratories | Antifungal dorrigocin derivatives |
US5393790A (en) * | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
AU1615895A (en) | 1994-03-31 | 1995-10-12 | Bristol-Myers Squibb Company | Imidazole-containing inhibitors of farnesyl protein transferase |
US5523430A (en) * | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
US5510510A (en) * | 1994-05-10 | 1996-04-23 | Bristol-Meyers Squibb Company | Inhibitors of farnesyl protein transferase |
US6358932B1 (en) * | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6391636B1 (en) * | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5571792A (en) * | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
CA2155448A1 (fr) | 1994-08-11 | 1996-02-12 | Katerina Leftheris | Inhibiteurs de la farnesyl-proteine-transferase |
EP0701907A1 (fr) | 1994-09-13 | 1996-03-20 | Agfa-Gevaert N.V. | Elément donneur de colorant pour utilisation dans un procédé de transfert thermique de colorant |
US6037136A (en) * | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
US5741789A (en) * | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US6001866A (en) | 1995-10-05 | 1999-12-14 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
US6020343A (en) * | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
WO1997019086A1 (fr) * | 1995-11-17 | 1997-05-29 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Derives d'epothilone, leur preparation et leur utilisation |
EP0882718B1 (fr) * | 1995-12-28 | 2005-08-31 | Fujisawa Pharmaceutical Co., Ltd. | Derives du benzimidazole |
GB9602029D0 (en) * | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
DE69739003D1 (de) * | 1996-04-12 | 2008-10-30 | Searle Llc | Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren |
AU728701B2 (en) * | 1996-05-23 | 2001-01-18 | Applied Research Systems Ars Holding N.V. | Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same |
US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
FR2751649B1 (fr) * | 1996-07-26 | 1998-08-28 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU756699B2 (en) * | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6127380A (en) * | 1997-02-18 | 2000-10-03 | American Home Products Corporation | 4-aminoalkoxy-1H-benzoimidazoles |
US5932600A (en) * | 1997-03-14 | 1999-08-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
DE69816280T2 (de) * | 1997-03-14 | 2004-05-27 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren des impdh-enzyms |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
AU744297B2 (en) * | 1997-07-03 | 2002-02-21 | Neurogen Corporation | Certain diarylimidazole derivatives; a new class of NPY specific ligands |
SI9700186B (sl) * | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
FR2766822B1 (fr) * | 1997-07-30 | 2001-02-23 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6204467B1 (en) * | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
TR200003472T2 (tr) * | 1998-05-22 | 2001-09-21 | Smithkline Beecham Corporation | Yeni 2-alkil ikameli imidazol bileşikler |
US6420555B1 (en) * | 1998-06-16 | 2002-07-16 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Imidazolyl derivatives |
FR2780973B1 (fr) * | 1998-07-09 | 2001-10-05 | Hoechst Marion Roussel Inc | Procede de preparation du 4-(3-pyridinyl)-1h-imidazole, et les intermediaires mis en oeuvre |
DE19834751A1 (de) * | 1998-08-01 | 2000-02-03 | Boehringer Ingelheim Pharma | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6211177B1 (en) * | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
US7351834B1 (en) * | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
BR0010599A (pt) | 1999-04-12 | 2002-02-13 | Aventis Pharma Ltd | Compostos de heteroarila bicìclicos substituìdos como antagonistas de integrina |
WO2001001986A1 (fr) | 1999-07-02 | 2001-01-11 | Lipton Stuart A | Procede pour reduire une blessure neuronale ou empecher l'apoptose |
ES2218391T3 (es) | 2000-03-06 | 2004-11-16 | Smithkline Beecham Plc | Derivados de imidazol como inhibidores de raf-cinasa. |
WO2001072712A1 (fr) | 2000-03-24 | 2001-10-04 | Cor Therapeutics, Inc. | Inhibiteurs du facteur xa sous forme d'isoquinolone |
AU2001249397A1 (en) | 2000-03-24 | 2001-10-08 | Cor Therapeutics, Inc. | Oxindole inhibitors of factor xa |
JP2001322903A (ja) | 2000-05-15 | 2001-11-20 | Kumiai Chem Ind Co Ltd | 農園芸用殺菌剤組成物 |
WO2002009761A2 (fr) * | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Polytherapie par antagoniste d'aldosterone epoxy-steroidien et inhibiteur calcique pour le traitement de l'insuffisance cardiaque congestive |
AU2001285349A1 (en) * | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The University Of Arkansas | Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 |
JP4734705B2 (ja) | 2000-10-31 | 2011-07-27 | 三菱化学株式会社 | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
DE10060292A1 (de) * | 2000-12-05 | 2002-06-20 | Aventis Pharma Gmbh | Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament |
MXPA03005298A (es) * | 2000-12-15 | 2003-10-06 | Vertex Pharma | Inhibidores de girasa y usos de los mismos. |
TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
US7144909B2 (en) * | 2001-02-08 | 2006-12-05 | Karo Bio Ab | Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands |
JP2004525140A (ja) * | 2001-03-26 | 2004-08-19 | ユニサーチ リミテッド | ガンの治療方法及び該治療方法に使用する組成物 |
BR0208956A (pt) | 2001-04-16 | 2004-07-13 | Tanabe Seiyaku Co | Abridor de canais de k ativados por cálcio de grande condutância |
US6855714B2 (en) * | 2001-07-06 | 2005-02-15 | Schering Aktiengesellschaft | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
WO2003024899A2 (fr) | 2001-09-17 | 2003-03-27 | Bristol-Myers Squibb Company | Acides hydroxamiques cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace) |
WO2003030902A1 (fr) * | 2001-10-09 | 2003-04-17 | Tularik Inc. | Derives d'imidazole comme agents anti-inflammatoires |
US7039413B2 (en) * | 2001-10-24 | 2006-05-02 | Ntt Docomo, Inc. | Mobile station transfer control system, cell transfer control method, mobile station, cell transfer control method at mobile station, cell transfer control program, control apparatus, and allocating method of communication resources |
TW200300140A (en) | 2001-11-14 | 2003-05-16 | Novartis Ag | Organic compounds |
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
JP4136395B2 (ja) | 2002-02-22 | 2008-08-20 | クミアイ化学工業株式会社 | 農園芸用殺菌剤組成物 |
US8299108B2 (en) * | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
SI1499311T1 (sl) * | 2002-03-29 | 2010-03-31 | Novartis Vaccines & Diagnostic | Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze |
JP4429738B2 (ja) | 2002-04-25 | 2010-03-10 | 帝人株式会社 | Ccr3拮抗作用を有する4,4−二置換ピペリジン誘導体 |
TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
WO2004014881A2 (fr) | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | Nouveaux composes |
JP4547271B2 (ja) * | 2002-09-18 | 2010-09-22 | ファイザー・プロダクツ・インク | トランスフォーミング増殖因子(tgf)阻害剤としての新規イミダゾール化合物 |
WO2004035056A1 (fr) | 2002-10-13 | 2004-04-29 | Neurosearch A/S | Utilisation de medicaments bloquant les canaux skca pour lutter contre la maladie de parkinson |
CA2502356A1 (fr) | 2002-10-15 | 2004-04-29 | Synta Pharmaceuticals Corp. | Nouveaux composes |
US20050054705A1 (en) * | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
EP2258365B1 (fr) * | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Utilisation de composés organiques pour potentialiser l'immunité |
PE20050157A1 (es) | 2003-05-20 | 2005-05-17 | Novartis Ag | Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar) |
CA2527079A1 (fr) | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Composes heterocycliques permettant de prevenir et de traiter des troubles associes a une perte osseuse excessive |
WO2005005421A1 (fr) | 2003-07-08 | 2005-01-20 | Novartis Ag | Composes benzenesulfonylamino, et compositions pharmaceutiques contenant ces composes |
US20060205740A1 (en) | 2003-08-14 | 2006-09-14 | Reno Michael J | Chemical compounds |
DK2392564T3 (da) | 2003-09-26 | 2014-01-13 | Exelixis Inc | c-Met-modulatorer og anvendelsesfremgangsmåder |
ATE435015T1 (de) | 2003-10-16 | 2009-07-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
WO2005073224A2 (fr) | 2004-01-23 | 2005-08-11 | Amgen Inc | Composes et methodes d'utilisation de ces derniers |
PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
ATE459338T1 (de) * | 2006-07-21 | 2010-03-15 | Novartis Ag | Formulierungen für benzimidazolylpyridylether |
-
2006
- 2006-08-29 PE PE2006001051A patent/PE20070335A1/es not_active Application Discontinuation
- 2006-08-29 TW TW095131916A patent/TWI387592B/zh not_active IP Right Cessation
- 2006-08-29 TW TW095131838A patent/TW200804345A/zh unknown
- 2006-08-29 PE PE2006001050A patent/PE20070427A1/es not_active Application Discontinuation
- 2006-08-30 NZ NZ565450A patent/NZ565450A/en not_active IP Right Cessation
- 2006-08-30 SI SI200631026T patent/SI1924577T1/sl unknown
- 2006-08-30 US US11/513,959 patent/US7482367B2/en active Active
- 2006-08-30 DE DE602006021036T patent/DE602006021036D1/de active Active
- 2006-08-30 AU AU2006284666A patent/AU2006284666B2/en not_active Ceased
- 2006-08-30 AU AU2006287688A patent/AU2006287688B2/en active Active
- 2006-08-30 PL PL06824870T patent/PL1926722T3/pl unknown
- 2006-08-30 PT PT06790127T patent/PT1924577E/pt unknown
- 2006-08-30 JP JP2008529291A patent/JP5210867B2/ja not_active Expired - Fee Related
- 2006-08-30 CA CA2620472A patent/CA2620472C/fr active Active
- 2006-08-30 AT AT06824870T patent/ATE526325T1/de active
- 2006-08-30 EA EA200800441A patent/EA014230B1/ru not_active IP Right Cessation
- 2006-08-30 BR BRPI0615314-3A patent/BRPI0615314A2/pt not_active IP Right Cessation
- 2006-08-30 WO PCT/US2006/034112 patent/WO2007027950A1/fr active Application Filing
- 2006-08-30 PL PL06790127T patent/PL1924577T3/pl unknown
- 2006-08-30 KR KR1020087005202A patent/KR20080039965A/ko active IP Right Grant
- 2006-08-30 SM SM200800022T patent/SMP200800022B/it unknown
- 2006-08-30 PT PT06824870T patent/PT1926722E/pt unknown
- 2006-08-30 AR ARP060103801A patent/AR057109A1/es unknown
- 2006-08-30 GT GT200600394A patent/GT200600394A/es unknown
- 2006-08-30 MY MYPI20080108A patent/MY148694A/en unknown
- 2006-08-30 RS RS20110583A patent/RS52099B/en unknown
- 2006-08-30 ES ES06824870T patent/ES2374451T3/es active Active
- 2006-08-30 EP EP06790127A patent/EP1924577B1/fr active Active
- 2006-08-30 NI NI200800060A patent/NI200800060A/es unknown
- 2006-08-30 WO PCT/US2006/034088 patent/WO2007030377A1/fr active Application Filing
- 2006-08-30 DK DK06824870.7T patent/DK1926722T3/da active
- 2006-08-30 JP JP2008529285A patent/JP5210866B2/ja active Active
- 2006-08-30 EP EP06824870A patent/EP1926722B1/fr active Active
- 2006-08-30 KR KR1020087005201A patent/KR20080039964A/ko active IP Right Grant
- 2006-08-30 AT AT06790127T patent/ATE503751T1/de active
- 2006-08-30 BR BRPI0615309-7A patent/BRPI0615309B1/pt not_active IP Right Cessation
- 2006-08-30 SI SI200631203T patent/SI1926722T1/sl unknown
- 2006-08-30 AR ARP060103802A patent/AR055622A1/es unknown
- 2006-08-30 DK DK06790127.2T patent/DK1924577T3/da active
- 2006-08-30 GE GEAP200610552A patent/GEP20105004B/en unknown
- 2006-08-30 US US11/513,745 patent/US20070049622A1/en not_active Abandoned
- 2006-08-30 CA CA002619966A patent/CA2619966A1/fr not_active Abandoned
- 2006-08-30 MY MYPI20080095A patent/MY163886A/en unknown
- 2006-08-30 NZ NZ565451A patent/NZ565451A/en not_active IP Right Cessation
-
2008
- 2008-01-28 IL IL189080A patent/IL189080A/en not_active IP Right Cessation
- 2008-02-03 IL IL189194A patent/IL189194A/en not_active IP Right Cessation
- 2008-02-07 CR CR9716A patent/CR9716A/es not_active Application Discontinuation
- 2008-02-21 EC EC2008008210A patent/ECSP088210A/es unknown
- 2008-02-25 EC EC2008008218A patent/ECSP088218A/es unknown
- 2008-02-25 CU CU20080027A patent/CU23784B7/es not_active IP Right Cessation
- 2008-02-28 TN TNP2008000088A patent/TNSN08088A1/en unknown
- 2008-02-28 HN HN2008000317A patent/HN2008000317A/es unknown
- 2008-02-28 TN TNP2008000089A patent/TNSN08089A1/en unknown
- 2008-03-11 MA MA30737A patent/MA29915B1/fr unknown
- 2008-03-11 MA MA30738A patent/MA29772B1/fr unknown
- 2008-03-26 NO NO20081476A patent/NO20081476L/no not_active Application Discontinuation
- 2008-05-05 US US12/151,995 patent/US7767820B2/en not_active Expired - Fee Related
- 2008-07-24 HK HK08108224.3A patent/HK1117519A1/xx not_active IP Right Cessation
- 2008-07-25 HK HK08108275.1A patent/HK1117523A1/xx not_active IP Right Cessation
- 2008-12-05 US US12/315,779 patent/US7732465B2/en active Active
-
2010
- 2010-04-13 US US12/759,578 patent/US8592459B2/en active Active
- 2010-06-18 US US12/818,971 patent/US20100256375A1/en not_active Abandoned
-
2011
- 2011-04-29 HR HR20110312T patent/HRP20110312T1/hr unknown
- 2011-06-27 CY CY20111100607T patent/CY1111871T1/el unknown
- 2011-12-06 CY CY20111101214T patent/CY1112157T1/el unknown
- 2011-12-15 HR HR20110939T patent/HRP20110939T1/hr unknown
-
2012
- 2012-12-03 JP JP2012264552A patent/JP2013060457A/ja not_active Withdrawn
- 2012-12-03 JP JP2012264553A patent/JP2013060458A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29772B1 (fr) | Benzimidazoles substitues et procedes de preparation | |
MA30289B1 (fr) | Dérivés d'amines | |
MA29692B1 (fr) | Derives de la xanthine en tant qu'agonistes selectifs du hm74a | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
MA27668A1 (fr) | 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
MA31894B1 (fr) | Composes organiques | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
TNSN07070A1 (fr) | Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA30089B1 (fr) | (arylsulfonyl)-pyrasolopiperidines | |
MA31419B1 (fr) | Derives de pyridine | |
TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
MA28747B1 (fr) | Dérivés de pyridine | |
MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
MA31084B1 (fr) | Derives de piperidine agonistes de gpcr | |
MA27654A1 (fr) | DERIVES HEXAHYDROPYRAZINO [1,2-a]-4,7-DIONE SUBSTITUES, METHODE POUR LEUR PRODUCTION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS | |
DE60131967D1 (de) | Nr1h4-kern-rezeptor-bindende verbindungen | |
MA26864A1 (fr) | Antagonistes du facteur de liberation de corticotrophine. | |
MA32627B1 (fr) | Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase | |
MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
MA27725A1 (fr) | Benzopyrannes utiles pour le traitement d'etats inflammatoires | |
TN2015000547A1 (fr) | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. |